Lexicon Pharmaceuticals I... (LXRX)
NASDAQ: LXRX
· Real-Time Price · USD
0.68
-0.02 (-3.00%)
At close: May 12, 2025, 3:59 PM
0.69
1.21%
After-hours: May 12, 2025, 07:19 PM EDT
-3.00% (1D)
| Bid | 0.67 |
| Market Cap | 246.05M |
| Revenue (ttm) | 31.08M |
| Net Income (ttm) | -200.4M |
| EPS (ttm) | -0.63 |
| PE Ratio (ttm) | -1.08 |
| Forward PE | -2.49 |
| Analyst | Hold |
| Ask | 0.72 |
| Volume | 4,529,847 |
| Avg. Volume (20D) | 15,600,508 |
| Open | 0.70 |
| Previous Close | 0.70 |
| Day's Range | 0.65 - 0.72 |
| 52-Week Range | 0.28 - 2.45 |
| Beta | 1.08 |
About LXRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LXRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LXRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Lexicon Pharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+64.13%
Lexicon Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
2 months ago
-58.17%
Lexicon Pharmaceuticals shares are trading lower after the company announced topline results from its PROGRESS Phase 2b study of pilavapadin. Despite the study not meeting statistical significance in its primary endpoint, the 10 mg dose showed clear clinical benefits over placebo.
2 months ago · seekingalpha.com
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call TranscriptLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate S...
